This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

April 2012 KonLin Letter Cites Cutting-Edge Technology For Stem Cells And Treatments For Cancer And Diabetes, And Reaffirms Buy Recommendation

Stocks in this article: NVLX

Nuvilex, Inc. (OTCQB: NVLX) reports Konrad Kuhn has included Nuvilex in his most recent KonLin Letter with a Buy recommendation, citing the company’s unique cell encapsulation technology for use with stem cells and treatment of pancreatic cancer and diabetes. He set the first target price at $0.50-0.60 and reconfirmed his target of $1-2.

“The KonLin Letter” is considered an authority on low-priced stocks, has consistently been one of the leading publications on Wall Street, and is rated one of the best performing market letters in the nation. Therefore, we were excited to learn of our inclusion in his private subscription-based letter. The April 2012 KonLin Letter stated, “NVLX represents one of the most remarkable investments in health care in decades.”

The KonLin Letter specializes in stocks under $10, with emphasis on emerging growth and special situations poised for explosive price appreciation. Konrad Kuhn's economic forecasts have been extremely accurate for over three decades. That stellar record puts him among the very few market analysts who successfully predicted: the 1987 market crash/correction, the 1998 "selling climax" and the 2000 NASDAQ crash, the bear markets of 2001 and 2002, the ongoing 7-year secular bull market in small- and micro-cap stocks, and the "07-08" financial meltdown.

As a result of his analysis, Mr. Kuhn commented, “Most companies only have expertise in one treatment category. By buying NVLX, investors have an opportunity to buy stock in what will likely become one of the leading companies treating cancer, diabetes, and stem cell utilization. Since the NVLX delivery system can be used in so many therapies, the market opportunity is in the tens of billions, and leading drug companies will likely partner or license technology from NVLX to improve their own drugs and maintain their market shares.”

In justifying the 1 st target price, KonLin stated, “Leading pharmaceutical firms in each treatment segment could seek development and marketing partnerships with NVLX worth $50–100 mil. in order to gain access to the revolutionary NVLX cell technology for converting their best-selling drugs. Once the SG Austria deal is closed, investors should expect a flurry of development activity which will serve as the catalyst for a steady rise in the stock on its way to our 1st target of .50-.60.”

About Nuvilex

Nuvilex, Inc. (OTCQB: NVLX) is an emerging international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Substantial effort of our corporate activities, alone and in concert with SG Austria, are near completion, ultimately driving our strong future together. Our company’s clinical offerings will include cancer, diabetes and other treatments using the company’s industry-leading cell and gene therapy expertise and cutting-edge, live-cell encapsulation technology.

Safe Harbor Statement

This press release contains forward-looking statements described within the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs